Amylin's long-delayed diabetes drug gets FDA nod
Amylin Pharmaceuticals won approval Friday for its long-delayed diabetes drug Bydureon, a next-generation treatment that requires fewer injections than the company's 7-year old diabetes medicine, Byetta.
Jan 28, 2012
0
0